[go: up one dir, main page]

SG11201510035UA - Method for upregulating antigen expression - Google Patents

Method for upregulating antigen expression

Info

Publication number
SG11201510035UA
SG11201510035UA SG11201510035UA SG11201510035UA SG11201510035UA SG 11201510035U A SG11201510035U A SG 11201510035UA SG 11201510035U A SG11201510035U A SG 11201510035UA SG 11201510035U A SG11201510035U A SG 11201510035UA SG 11201510035U A SG11201510035U A SG 11201510035UA
Authority
SG
Singapore
Prior art keywords
antigen expression
upregulating
upregulating antigen
expression
antigen
Prior art date
Application number
SG11201510035UA
Inventor
Roy H Larsen
Ada Repetto-Llamazares
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of SG11201510035UA publication Critical patent/SG11201510035UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201510035UA 2013-06-07 2014-06-06 Method for upregulating antigen expression SG11201510035UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201370313 2013-06-07
PCT/EP2014/061824 WO2014195460A1 (en) 2013-06-07 2014-06-06 Method for upregulating antigen expression

Publications (1)

Publication Number Publication Date
SG11201510035UA true SG11201510035UA (en) 2016-01-28

Family

ID=50896309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510035UA SG11201510035UA (en) 2013-06-07 2014-06-06 Method for upregulating antigen expression

Country Status (19)

Country Link
US (2) US20160101199A1 (en)
EP (2) EP3332813B1 (en)
JP (2) JP6335284B2 (en)
KR (1) KR102033819B1 (en)
CN (2) CN105451781B (en)
AU (1) AU2014276827B2 (en)
BR (1) BR112015030457A2 (en)
CA (1) CA2911962A1 (en)
DK (2) DK3003402T3 (en)
ES (2) ES2662964T3 (en)
HK (1) HK1256497B (en)
IL (1) IL242892A (en)
MX (1) MX367346B (en)
NO (1) NO3003402T3 (en)
PH (1) PH12015502713B1 (en)
RU (1) RU2681953C2 (en)
SG (1) SG11201510035UA (en)
UA (1) UA119443C2 (en)
WO (1) WO2014195460A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2546674Y2 (en) 1991-02-27 1997-09-03 エヌオーケー株式会社 Cross-shaped yarn bundle manufacturing equipment for hollow fiber membranes
SG10202001677QA (en) 2010-03-12 2020-04-29 Debiopharm International S A Cd37-binding molecules and immunoconjugates thereof
WO2016135200A1 (en) * 2015-02-26 2016-09-01 Sciencons AS Radiopharmaceutical solutions with advantageous properties
JP6979877B2 (en) 2015-06-08 2021-12-15 デビオファーム インターナショナル, エス. アー. Combination of anti-CD37 immunoconjugate and anti-CD20 antibody
MX2018002467A (en) 2015-08-28 2018-06-15 Debiopharm Int Sa Antibodies and assays for detection of cd37.
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
WO2019027973A1 (en) * 2017-07-31 2019-02-07 Actinium Pharmaceuticals Inc. Treatments for a hematological malignancy
ES3039245T3 (en) * 2017-11-10 2025-10-20 Actinium Pharmaceuticals Inc Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies
JP2021504341A (en) * 2017-11-22 2021-02-15 ノルディック ナノベクター エーエスエー Radioimmune complex as a treatment for NHL in combination with other drugs
JP2021525735A (en) 2018-05-30 2021-09-27 デビオファーム インターナショナル, エス. アー. Anti-CD37 immunoconjugate dosing regimen
CN117285631A (en) * 2023-11-24 2023-12-26 原子高科股份有限公司 Lu-177 labelled MUC1 antibodies for radioimmunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP2990054A1 (en) * 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
KR20040088572A (en) * 2002-03-01 2004-10-16 이뮤노메딕스, 인코오포레이티드 Bispecific antibody point mutations for enhancing rate of clearance
PT1912675E (en) * 2005-07-25 2014-05-09 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
TWI409079B (en) * 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of atypical fucosylated CD20 antibody and bendamustine
NO331080B1 (en) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmune conjugates, pharmaceutical compositions and kits comprising the same and their use
PL3272364T3 (en) * 2011-12-13 2021-04-06 Nordic Nanovector Asa Chimeric therapeutic anti-cd37 antibodie hh1
US20130309224A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab

Also Published As

Publication number Publication date
CN105451781A (en) 2016-03-30
NO3003402T3 (en) 2018-06-16
JP2018150323A (en) 2018-09-27
EP3332813B1 (en) 2019-05-29
US20160101199A1 (en) 2016-04-14
RU2015154447A3 (en) 2018-03-07
MX367346B (en) 2019-08-15
EP3003402B1 (en) 2018-01-17
WO2014195460A1 (en) 2014-12-11
JP2016520640A (en) 2016-07-14
AU2014276827A1 (en) 2016-01-28
ES2741643T3 (en) 2020-02-11
RU2015154447A (en) 2017-07-17
EP3332813A1 (en) 2018-06-13
EP3003402A1 (en) 2016-04-13
HK1256497B (en) 2020-06-05
DK3332813T3 (en) 2019-06-24
JP6335284B2 (en) 2018-05-30
MX2015016832A (en) 2016-05-31
JP6590985B2 (en) 2019-10-16
DK3003402T3 (en) 2018-04-16
KR20160039178A (en) 2016-04-08
ES2662964T3 (en) 2018-04-10
PH12015502713B1 (en) 2020-02-28
CA2911962A1 (en) 2014-12-11
CN108939065A (en) 2018-12-07
HK1217438A1 (en) 2017-01-13
BR112015030457A2 (en) 2017-08-22
US10646599B2 (en) 2020-05-12
KR102033819B1 (en) 2019-10-17
US20190008989A1 (en) 2019-01-10
CN105451781B (en) 2018-07-27
RU2681953C2 (en) 2019-03-14
AU2014276827B2 (en) 2018-11-15
PH12015502713A1 (en) 2016-03-14
UA119443C2 (en) 2019-06-25
IL242892A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
GB201314695D0 (en) Method
GB201320351D0 (en) Method
IL242892A (en) Method for upregulating antigen expression
GB201309057D0 (en) Method
GB201322851D0 (en) Method
GB201316744D0 (en) Method
GB201306544D0 (en) Method for releasing overlaps
GB201309928D0 (en) Method
GB201301857D0 (en) Method
GB201313249D0 (en) Method
GB201300409D0 (en) Method
GB201309654D0 (en) Method
GB201305714D0 (en) Method
GB201301233D0 (en) Method
GB201311385D0 (en) Method
GB201301094D0 (en) Method
PT2821771T (en) Testing method
GB201312609D0 (en) Method
GB201318490D0 (en) Method
GB201314054D0 (en) Method
GB201311389D0 (en) Method
PT2892308T (en) Method for via-pin filling
GB201420652D0 (en) Method
GB201315691D0 (en) Inspection method
GB201317826D0 (en) Method